And elsewhere.
An FDA advisory panel met this morning to
discuss regulatory approval of the Alzheimer's drug Lemine.
The FDA granted the drug accelerated approval back in January after
research showed its effectiveness in removing toxic plaques from the brain.
Late stage trials show that the drug slowed
cognitive decline by 27% in early Alzheimer's patients
and the company behind the drug Biogen
trading today. Take a look. It is higher on the news.
Well, the NASDAQ halted trading this morning as the FDA review took place
but the US Medicare health plan says it's going to pay for the treatment of
doctors participate in a health agency database
that would track how the drug works.
The FDA is expected to make its decision on the approval by July six.
And if it does go through the drug would be the
first of its class of drugs to achieve a regulatory approval.
Well, according to the Alzheimer's Association,
more than six million Americans are affected by the disease.